GlassScriptPhysician profile
Michael L Gambill
NPI 1679769202
$2,379.18
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $614 · 2021: $590.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $449.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $323.97 | 2019-2021 | |
| Amgen INC. | $268.52 | 2019-2021 | |
| Biotronik INC. | $145.01 | 2019-2021 | |
| Amarin Pharma, INC. | $137.91 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.86 | 2019-2021 | |
| Abiomed | $118.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $107.76 | 2019-2021 | |
| Novo Nordisk INC | $87.29 | 2021 | |
| Sanofi-Aventis U.S. LLC | $75.19 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $70.18 | 2019 | |
| Pfizer INC. | $67.74 | 2019-2021 | |
| Braemar Manufacturing, LLC | $65.11 | 2019 | |
| Philips North America LLC | $53.69 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $52.79 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.48 | 2019 | |
| Bardy Diagnostics, INC. | $37.29 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $33.74 | 2021 | |
| Merck Sharp & Dohme LLC | $30.22 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.89 | 2021 | |
| Chiesi USA, INC. | $20.51 | 2019 | |
| Irhythm Technologies, INC. | $18.67 | 2020 | |
| Medtronic Vascular, INC. | $14.86 | 2019 | |
| Lundbeck LLC | $14.55 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gambill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.